NYMX Key Statistics, Chart & Performance
The current stock price of NYMX is 0.2 USD. In the past month the price decreased by -50.94%. In the past year, price decreased by -51.16%.
NYMX Technical Analysis
NYMX Financial Highlights
Over the last trailing twelve months NYMX reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 82.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NYMX Forecast & Estimates
NYMX Ownership
NYMX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About NYMX
Company Profile
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. The company is headquartered in Saint-Laurent, Quebec. The firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (prostate enlargement, BPH) and for low-grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company’s lead drug candidate for BPH FT has completed Phase III development in more than 70 clinical centers in the United States. FT has completed a phase II trial in the United States. The company has also developed the AlzheimAlert test. The firm operates in Canada, the United States and Switzerland.
Company Info
NYMOX PHARMACEUTICAL CORP
St. Laurent, 9900 Cavendish Blvd Suite 306
Saint-Laurent QUEBEC H4M 2V2 CA
CEO: Paul Averback
Employees: 3
Phone: 18009369669.0
NYMOX PHARMACEUTICAL CORP / NYMX FAQ
What does NYMOX PHARMACEUTICAL CORP do?
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. The company is headquartered in Saint-Laurent, Quebec. The firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (prostate enlargement, BPH) and for low-grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company’s lead drug candidate for BPH FT has completed Phase III development in more than 70 clinical centers in the United States. FT has completed a phase II trial in the United States. The company has also developed the AlzheimAlert test. The firm operates in Canada, the United States and Switzerland.
What is the current price of NYMX stock?
The current stock price of NYMX is 0.2 USD. The price decreased by -19.68% in the last trading session.
Does NYMX stock pay dividends?
NYMX does not pay a dividend.
What is the ChartMill technical and fundamental rating of NYMX stock?
NYMX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the market capitalization of NYMX stock?
NYMOX PHARMACEUTICAL CORP (NYMX) has a market capitalization of 18.10M USD. This makes NYMX a Nano Cap stock.
Can you provide the upcoming earnings date for NYMOX PHARMACEUTICAL CORP?
NYMOX PHARMACEUTICAL CORP (NYMX) will report earnings on 2023-08-15.